Tissue fibrosis refers to growths of fibrous connective tissue that join surfaces not normally connected within the body. They can form anywhere, but frequently arise as a result of surgery, These surgical adhesions are often more dangerous than ones that spontaneously develop and can be life-threatening.
Tissue fibrosis, commonly referred to as scar tissue, resulting from abdominal and pelvic surgery commonly causes chronic pain, bowel obstruction, and infertility in women and is the number one cause of post-surgical complications for these procedures.
No drug treatments currently exist for fibrosis, and surgeries attempting to reverse its effects worsen the condition about 70 percent of the time.
Currently, the most commonly used method for preventing postoperative adhesion is the use of barrier materials, which are thin films placed strategically around the surgical site to physically block fibrotic tissue from joining tissues or organs. These products are, at best, only about 50 percent effective at preventing the development of adhesion and do not actively promote healthy healing of tissues.
Temple believes postoperative tissue fibrosis is a serious quality-of-life issue, and we seek to address this condition using top-notch science.
Tissue fibrosis is a persistent complication for many patients. At Temple, we are investing millions of dollars into developing solutions for fibrosis, bringing us closer than ever to delivering a new breakthrough to patients.
“Tissue fibrosis causes adhesions which are a big problem, and we would use this drug in every procedure.”
Temple is developing an impactful product that dramatically reduces tissue fibrosis in patients undergoing abdominal and pelvic surgery.
The drug, TTX333, is easily administered during surgery, both open and laparoscopic, allowing it to act immediately to prevent the formation of adhesions and promote healthy tissue regeneration at the surgical site.
The formation of fibrotic tissue following surgery is a result of the physical trauma and low oxygen levels experienced by cells during the procedure. This disrupts the Krebs cycle, a key process in cellular respiration, which can lead to the development of fibrosis.
Working on the cellular level, our investigative therapy will be the first therapeutic targeting tissue fibrosis and will act throught the abdominal area with twice the efficacy of existing approaches.
• CNS & Neurological Disorders - Drug Targets, April 2022
•Reproductive Sciences Journal, December 2019
•Presentations & Posters
